What Tempus AI's FY2025 10-K says: 11 signals
Tempus AI filed its latest 10-K with the SEC on Feb 24, 2026. It discusses margin pressure, data investment and acquisition completed.
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
- Filed
- Feb 24, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Tempus AI's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 11 signals
Tempus focused on realizing benefits from acquisitions of Paige.AI, Ambry Genetics, and Deep 6 AI.
This effort is critical to realizing the expected financial and strategic benefits of the deals.
AI
Tempus is building a core platform using Generative AI to unify siloed healthcare data.
Tempus's primary strategy is to build and scale its platform using AI, including generative and agentic AI, to structure and analyze vast amounts of disconnected healthcare data.
AIgenerative AIagentic AIcloud computing
Profitability challenged by third-party payer reimbursement and coverage decisions.
The company's financial performance is heavily dependent on securing favorable reimbursement and coverage from third-party payers.
Building a massive data platform with over 700 unique data connections to healthcare institutions.
Tempus has established a network of over 700 data connections to aggregate siloed clinical and molecular data, creating a massive proprietary dataset.
data pipelinesmultimodal data
The company has flagged its ability to realize expected benefits from its recent acquisitions as a key uncertainty.
Tempus is strategically expanding beyond oncology into neurology and cardiology.
A key growth initiative for Tempus is to apply its data and AI platform to new disease areas, with neurology and cardiology already in progress.
AI
Tempus launching new AI-driven diagnostic products, including 'Next' and 'Algos'.
Tempus is focused on commercializing new AI-based products like 'Next' for oncology/cardiology care gaps and 'Algos' for algorithmic diagnostics.
AImachine learninggenerative AI
High operational costs of structuring vast, disconnected healthcare data impacting margins.
The company's core mission involves processing unstructured and siloed healthcare data, which is an expensive and complex operational challenge.
AI
Leveraging cloud computing to power its large-scale AI and data analytics platform.
The company's strategy to digitize, store, and analyze vast healthcare datasets with AI is enabled by advances in cloud computing.
cloud computingAIlarge language models
Showing 9 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns Tempus AI 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"tempus.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Tempus AI 10-K
When did Tempus AI file its latest 10-K?
What does Tempus AI's latest 10-K say about acquisition completed?
Where can I find Tempus AI's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .